Rhythm Pharmaceuticals Inc (RYTM): Next-Year EPS Estimate 78.06%
As of 2026-10-16, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 78.06%. Featured in our EPS revision report on 2026-06-24.
On 2026-10-16, analyst consensus for RYTM's next-year EPS growth shifted from 77.96% to 78.06% — a positive change of 0.10 percentage points. Current-year growth is projected at 5.28%.
What's Driving This
The primary driver is the analysts' upgrade of next-year EPS growth estimate from 74.71% to 77.75% on August 5, 2026. This follows positive clinical data presented at ENDO 2026, including interim Phase 2 results for setmelanotide in Prader-Willi syndrome, which likely prompted the upward revision. The stock continued to gain as the estimate edged up further to 77.78%, reflecting sustained momentum.
Generated 2026-08-13 from news as of 2026-08-13
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 78.06%
- EPS growth this year
- 5.28%
- EPS next quarter (est)
- -$0.71
- Last price
- $86.17
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-16 | 78.06% | 5.28% | -$0.71 | $86.17 |
| 2026-10-15 | 77.96% | 5.08% | -$0.71 | $87.97 |
| 2026-10-14 | 78.18% | 5.08% | -$0.71 | $86.71 |
| 2026-10-13 | 78.18% | 5.08% | -$0.71 | $86.61 |
| 2026-10-12 | 78.18% | 5.08% | -$0.71 | $89.82 |
| 2026-10-11 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-10 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-09 | 78.19% | 4.81% | -$0.71 | $90.78 |
| 2026-10-08 | 78.21% | 4.75% | -$0.72 | $89.64 |
| 2026-10-07 | 76.36% | 4.15% | -$0.72 | $88.45 |
| 2026-10-06 | 76.36% | 4.15% | -$0.72 | $90.77 |
| 2026-10-05 | 76.36% | 4.15% | -$0.72 | $92.45 |
| 2026-10-04 | 76.36% | 4.15% | -$0.72 | $92.83 |
| 2026-10-03 | 76.36% | 4.15% | -$0.72 | $92.83 |
| 2026-10-02 | 76.36% | 4.15% | -$0.72 | $92.83 |
| 2026-10-01 | 76.36% | 4.15% | -$0.72 | $93.41 |
| 2026-09-30 | 76.36% | 4.15% | -$0.72 | $95.21 |
| 2026-09-29 | 76.36% | 4.15% | -$0.72 | $95.71 |
| 2026-09-28 | 76.36% | 4.15% | -$0.72 | $98.56 |
| 2026-09-27 | 76.36% | 4.15% | -$0.72 | $98.66 |
| 2026-09-25 | 76.36% | 4.15% | -$0.72 | $98.66 |
| 2026-09-24 | 76.36% | 4.15% | -$0.72 | $98.31 |
| 2026-09-23 | 76.36% | 4.15% | -$0.72 | $98.24 |
| 2026-09-22 | 76.36% | 4.15% | -$0.72 | $99.27 |
| 2026-09-21 | 76.36% | 4.15% | -$0.72 | $98.83 |
| 2026-09-20 | 78.65% | 4.19% | -$0.72 | $97.71 |
| 2026-09-18 | 78.65% | 4.19% | -$0.72 | $97.71 |
| 2026-09-17 | 78.65% | 4.19% | -$0.72 | $99.02 |
| 2026-09-16 | 78.06% | 2.58% | -$0.73 | $98.01 |
| 2026-09-15 | 78.06% | 2.58% | -$0.73 | $96.77 |
Reports Featuring RYTM
Recent News
- Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call SummaryMoby
- Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingInvestor's Business Daily
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeGlobeNewswire
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine SocietyGlobeNewswire
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 198 days.
- Median return since detection
- -3.0%
- % of tickers in the green
- 43%
- Median return on winners
- +21.5%
- Large revisions captured
- 1886
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-10-16, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 78.06%, based on analyst consensus.
When was the latest EPS estimate revision for RYTM?▾
The most recent revision occurred on 2026-10-16, when analysts adjusted the next-year EPS growth estimate from 77.96% to 78.06%.
What sector and industry does Rhythm Pharmaceuticals Inc belong to?▾
Rhythm Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RYTM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rhythm Pharmaceuticals Inc (RYTM) appears here because it was detected by our daily top-EPS-revision-performer screen.